Sequence: Ac-rqikiwfqnrrmkwkkc-amide
| Experiment Id | EXP002449 |
|---|---|
| Paper | Lung Delivery Studies Using siRNA Conjugated to TAT(48-60) and Penetratin Reveal Peptide Induced Red |
| Peptide | Penetratin-siRNA |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 nmol intratracheal dose |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | covalent peptide-siRNA conjugate in PBS |
| Formulation Components | Penetratin CPP + p38 MAPK siRNA sequence C |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Male BALB/c mice; lung delivery by intratracheal administration |
| Administration Route | intratracheal administration |
| Output Type | p38 MAP kinase mRNA expression, lung distribution, innate immune markers |
| Output Value | 47 ± 9% p38 MAPK mRNA reduction at 6 h; penetratin peptide alone caused 30 ± 7% reduction |
| Output Units | |
| Output Notes | Not counted as delivery success because penetratin peptide alone reduced p38 MAPK mRNA, confounding interpretation of peptide-siRNA-mediated RNAi. Histology showed Cy3-siRNA uptake mainly in macrophages and scattered epithelial cells; penetratin conjugation did not alter the pattern in reported results. |
| Toxicity Notes | Penetratin-siRNA induced innate immune response, with increased TNF-α and IL-12p40 and elevated IFN-α |
| Curation Notes |